Curated news and analysis on clinical trials, drug approvals, and medical research.
Australia's Medical Research Future Fund announces two 2026 grant opportunities totaling $98 million for research infrastructure and international clinical trial collaborations.
CStone Pharmaceuticals received FDA IND clearance to begin a Phase II trial of CS2009, a trispecific antibody targeting PD-1, VEGF, and CTLA-4, in advanced solid tumors across nine cancer indications.
Eli Lilly committed $1 billion to build an AI-powered supercomputer with Nvidia for drug discovery, launching its TuneLab platform in September and establishing a co-innovation lab by January.
A phase IIa clinical trial found that a single intravenous dose of dimethyltryptamine (DMT) with psychological support rapidly reduced depressive symptoms in 34 adults with major depressive disorder, with improvements sustained for up to three months.
Researchers at Monash University have identified DNA sequence variations in mothers that modify the risk of birth defects from valproic acid, an anti-seizure medication, paving the way for a genetic test to identify who can safely take the drug during pregnancy.
The provided articles contain local crime reports and general news aggregation content with no medical or pharmaceutical information to synthesize.
CSL Seqirus announced that neffy adrenaline nasal spray has been approved in Australia for emergency treatment of anaphylaxis in adults and children 15kg+ and aged four years and over, marking the first new adrenaline administration method approved in over 30 years.
Nitride Global receives $1.25M AFWERX Direct-to-Phase II SBIR contract to develop its multilayer aluminum oxynitride substrate platform for next-generation defense power electronics and commercial applications.
The Indian Health Service announced it will phase out mercury-containing dental amalgams by 2027, citing environmental and health concerns. The move affects roughly 2.8 million patients and aligns with global efforts to reduce mercury exposure.
Researchers identified shared white matter alterations in the corpus callosum as a common biomarker across schizophrenia and bipolar disorder, supporting the concept of a psychosis spectrum rather than distinct disorders.
Mexican authorities killed Nemesio Oseguera Cervantes, known as 'El Mencho,' founder of the Jalisco New Generation Cartel, in a Sunday military operation aided by U.S. intelligence. The operation sparked widespread violence across western Mexico.
A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.
The American Psychiatric Association released a roadmap for the future DSM in January 2026, proposing to incorporate biomarkers and rename the manual to reflect scientific scope. A new conceptual framework suggests using electrical and chemical signals to explain mental disorders and human intelligence.
Savara Inc. announced the FDA has accepted its resubmitted Biologics License Application for MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis, with Priority Review granted and a target decision date of August 22, 2026.
Jammu and Kashmir government plans comprehensive Biotechnology Policy to leverage the Union Territory's rich biodiversity and medicinal plant wealth for India's growing bio-economy, with Rs 84.66 crore investment in two biotech parks.
New research shows the nervous system contributes to pancreatic cancer development before tumors fully form, with nerve fibers and support cells creating a self-sustaining loop that promotes cancer growth. Blocking nerve activity reduced tumor growth by nearly 50% in experiments.
BioAsia 2026 in Hyderabad attracted over 4,000 delegates and 500 companies, featuring AI-driven drug discovery platforms and showcasing Indian biotech innovations including BioVaram's regenerative medicine breakthrough.
Recent research explores plant-based diets' association with breast cancer risk, disparities in care for Black women in Canada, and survival outcomes for young women with breast cancer in Latin America.
NanoViricides has filed an orphan drug designation application with the FDA for NV-387 as a measles treatment, amid rising U.S. cases that reached 2,251 in 2025 with 3 deaths and 727 cases already reported in early 2026.
CAR-T cell therapy engineering advances at Tandem 2026 focus on reducing toxicity and improving access, while McGill researchers develop targeted nanoparticle immunotherapy for lymph node metastases with fewer side effects.
